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Background: The lack of noninvasive biomarkers of rejection remains a challenge in the accurate monitoring of
deeply buried nerve allografts and precludes optimization of therapeutic intervention. This study aimed to establish
the expression profile of circulating microRNAs (miRNAs) during nerve allotransplantation with or without
immunosuppression.
Results: Balb/c mice were randomized into 3 experimental groups, that is, (1) untreated isograft (Balb/c→ Balb/c),
(2) untreated allograft (C57BL/6→ Balb/c), and (3) allograft (C57BL/6→ Balb/c) with FK506 immunosuppression. A
1-cm Balb/c or C57BL/6 donor sciatic nerve graft was transplanted into sciatic nerve gaps created in recipient mice.
At 1, 3, 7, 10, and 14 d after nerve transplantation, nerve grafts, whole blood, and sera were obtained for miRNA
expression analysis with an miRNA array and subsequent validation with quantitative real-time PCR (qRT-PCR). Three
circulating miRNAs (miR-320, miR-762, and miR-423-5p) were identified in the whole blood and serum of the mice
receiving an allograft with FK506 immunosuppression, within 2 weeks after nerve allotransplantation. However,
these 3 circulating miRNAs were not expressed in the nerve grafts. The expression of all these 3 upregulated
circulating miRNAs significantly decreased at 2, 4, and 6 d after discontinuation of FK506 immunosuppression. In
the nerve graft, miR-125-3b and miR-672 were significantly upregulated in the mice that received an allograft with
FK506 only at 7 d after nerve allotransplantation.
Conclusions: We identified the circulating miR-320, miR-762, and miR-423-5p as potential biomarkers for
monitoring the immunosuppression status of the nerve allograft. However, further research is required to
investigate the mechanism behind the dysregulation of these markers and to evaluate their prognostic value in
nerve allotransplantation.
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Nerve allograft transplantation is now a clinical reality
for select patients who sustain a considerable nerve in-
jury with nerve defect [1]. During nerve regeneration
through the allograft, temporary immunosuppression is
required for the nerve allotransplantation to be success-
ful. Cyclosporin A has been used to increase the accept-
ance of peripheral nerve allografts [2-4], and the
immunosuppressive agent FK506 has been commonly* Correspondence: m93chinghua@gmail.com
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reproduction in any medium, provided the orused in nerve allotransplantation [5-9]. FK506 can enhance
nerve regeneration and accelerate functional recovery not
only in allograft but also in isograft- [10,11], crush- [12-14],
transection- [15-17], and conduit-based animal models
[18]. In a study involving neurohistomorphometric analyses
on rats given daily doses of FK506 at 0.25, 0.5, 1.0, or 2.0
mg/kg, significant improvements were seen in neurore-
generation for FK506 doses of 0.5 and 1.0 mg/(kg · d) [19].
With these doses of FK506, neuroregeneration was found
to be enhanced, but skin allograft rejection could not be
prevented [19]. The beneficial effects of FK506 on
neuroregeneration are not restricted to immediate adminis-
tration, but these effects are significantly diminished when
FK506 is administered at 3 d after nerve injury [17]. Cur-
rently, 3 d of pretreatment with FK506 and continued. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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distal graft site are recommended on the basis of clinical re-
sults obtained for human nerve allotransplantation [20].
Sufficient immunosuppression after nerve allotrans-
plantation is important for successful nerve regeneration
through the allograft. Moreover, successful neurore-
generation is also a key factor involved in the recent
emergence of composite tissue transplantation, including
whole limb or facial allografts. In addition, because the
peripheral nerve allografts provide sensation and func-
tion to the composite tissue allotransplants, preventing
nerve allograft rejection is an important step during the
transplantation of composite tissue allografts, which
comprise components with different antigenicities. Tis-
sues differ in their susceptibility to rejection [21]. The
skin, lung, and small bowel are among the most suscep-
tible to rejection; the kidney transplants show intermedi-
ate susceptibility; and the liver is one of the organs that
shows lower susceptibility to rejection [22]. The nerves
show intermediate susceptibility, with rejection of nerve
allografts typically occurring within 7 d of transplant-
ation in the absence of host immunosuppression [23].
For evaluation of the immunological response to the
nerve allograft, different methods such as the following
have been used in mice: enzyme-linked immunospot as-
says for INF-γ production [24,25]; mixed lymphocyte
cultures [23,26]; limiting dilution analysis [23], which
measures the frequency of defined clones of lymphocytes
responding to a specific antigen; and neurohistomor-
phometric analysis. However, all these approaches re-
quire sacrifice of the animal with harvest of the spleen
or nerves, which is not practical in the clinical setting.
Therefore, monitoring the immunological status of the
deeply buried nerve allograft without sacrificing the ani-
mal remains a challenge and requires further biomar-
kers that allow sensitive and accurate monitoring of
graft function as well as early and specific diagnosis of
rejection.
Sera and other body fluids contain cell-free DNA,
RNA, and circulating nucleic acids, which serve as po-
tential biomarkers [27]. One such biomarker that has
aroused interest in recent years is a small ∼ 22-nucleo-
tide (nt) noncoding RNA, which is called microRNA
(miRNA) [28], whose specific expression patterns in the
serum have been identified to contain fingerprints for
various diseases [29-31]. In addition, despite the pres-
ence of ubiquitous ribonucleases (RNases), the serum
miRNA levels are remarkably stable and reproducible
[32,33]. Further, biochemical analyses indicate that
miRNAs are resistant to RNase activity, extreme pH and
temperature, extended storage, and multiple freeze-thaw
cycles [34,35]. miRNA expression is tightly regulated in
a tunable, cell-specific, and time-dependent manner.
Moreover, secreted miRNAs offer additional advantages.First, most miRNA sequences are conserved across spe-
cies. Second, the expression of some miRNAs is specific
to tissues or biological stages. Third, miRNAs are active
moieties and should thus reflect physiological alterations
more directly than mRNAs [36]. Fourth, in contrast to
the levels of protein-based biomarkers, the levels of
miRNAs can be easily measured by quantitative real-
time PCR (qRT-PCR), allowing for high-precision signal
amplification. Moreover, the protein-based biomarkers
may have different posttranslational modifications that
can affect the accuracy of measurement, while miRNAs
are relatively homogeneous [37]. Fifth, the use of mul-
tiple miRNA expression in a cluster pattern to analyze
miRNAs in parallel increases the sensitivity and specifi-
city and provides an accessible diagnostic tool [34,36].
This study aims to establish the expression profile of cir-
culating miRNAs during nerve allotransplantation.
Methods
Experimental design
Male Balb/c and C57BL/6 mice (age, 10–12 weeks;
weight, 30–35 g) were purchased from BioLasco
(Yi-Lan, Taiwan). The Balb/c mice were randomized into
3 experimental groups: (1) untreated isograft, (2) un-
treated allograft, and (3) allograft with FK506 treatment.
Additional Balb/c and C57BL/6 mice served as sciatic
nerve isograft and allograft donors, respectively. These
species of mice were selected on the basis of disparity at
the MHC locus and prior experience with reciprocal
rejection of grafts between these murine strains. FK506
was administered subcutaneously at 1 mg/(kg · d)
throughout the experimental course, unless indicated
otherwise. At 1, 3, 7, 10, and 14 d after initial surgery
(n = 6 animals per group at each time point), sciatic
nerve grafts were harvested, and whole blood samples
were obtained. Additional sham-operated mice were
subjected to the same procedure, including opening of
the skin and muscle layers and exposing the sciatic
nerve, but without nerve transection or nerve grafting,
to measure the effect of FK506 injection on the expres-
sion of circulating miRNA. To test the effect of the dis-
continuation of FK506 treatment on the expression of
circulating miRNA, whole blood was drawn at 0, 2, 4,
and 6 d after discontinuation of FK506 injection in an
additional group of mice with allografts and immuno-
suppression for 7 d. The whole blood samples (1 mL per
mouse) were collected at the indicated times in tubes
containing anticoagulant. After the whole blood samples
were incubated at room temperature for 15 min, they
were centrifuged at 3,000 × g for 10 min, white blood
cells were slowly qRT-PCR removed from the corre-
sponding layers, and the serum was extracted and stored
at –80°C before processing for RNA analyses. All the
housing conditions and the surgical procedures,
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tional and institutional guidelines, and an Association
for Assessment and Accreditation of Laboratory Animal
Care (AAALAC)–accredited SPF facility was used. The
animal protocols were approved by the Institutional Ani-
mal Care and Use Committee (IACUC) of Kaohsiung
Chang Gung Memorial Hospital.
Surgical procedures
The mice were anesthetized by intraperitoneal injection of
an anesthetic cocktail consisting of 0.1 mg/g ketamine and
0.01 mg/g xylazine. The anesthetized mice were restrained
in a supine position on a heated pad to maintain the body
temperature at 37°C. Under aseptic conditions, with sterile
povidone/iodine preparation and 70% ethanol and sterile
instruments and drapes, the skin over the proximal right
hindlimb was incised, and the underlying biceps femoris
muscle was bluntly dissected to expose the sciatic nerve.
An established mouse sciatic nerve allotransplantation
model was used. In brief, 1-cm Balb/c or C57BL/6 donor
sciatic nerve grafts were transplanted in reverse orienta-
tion into 0.5-cm sciatic nerve gaps created in the recipient
Balb/c mice. Tension-free repair was then performed
under an operating microscope with three 11–0 nylon
(Ethicon Inc., Somerville, NJ) interrupted epineurial su-
tures under 40× magnification. The muscle was closed
with 5–0 vicryl sutures, and the skin with interrupted 5–0
nylon sutures. The animals were monitored to ensure ap-
propriate feeding and diet after surgery.
RNA isolation
Total RNA was extracted from the harvested nerve graft,
whole blood, and serum using the mirVana miRNA Isola-
tion Kit (Ambion, Austin, TX, USA). For the miRNA
array, the purified RNA yield was determined by the ab-
sorbance at 260 nm with an SSP-3000 Nanodrop spectro-
photometer (Infinigen Biotech, City of Industry, CA,
USA), and RNA quality was evaluated with a Bioanalyzer
2100 system (Agilent Technologies, Palo Alto, CA, USA).
miRNA array analysis
The Mouse & Rat miRNA OneArray® v3 (Phalanx Bio-
tech Group, Hsinchu, Taiwan) contains a total of 4104
probes, including 144 experimental control probes, 1111
unique mouse miRNA probes, and 680 rat miRNA
probes, based on miRBase version 17. Mouse genome-
wide miRNA microarray analysis was performed by
Phalanx Biotech. Briefly, fluorescent targets were pre-
pared from 2.5 μg of total RNA with the miRNA ULS™
Labeling Kit (Kreatech Diagnostics, Amsterdam, the
Netherlands). Labeled miRNA targets enriched using
NanoSep 100K (Pall Corporation, Port Washington, NY,
USA) were hybridized to the Mouse & Rat miRNA
OneArray® v3 in Phalanx hybridization buffer, using theOneArray® Hybridization Chamber. After overnight
hybridization at 37°C, nonspecifically bound targets were
removed by 3 washing steps (wash I, at 37°C for 5 min;
wash II, at 37°C for 5 min and at 25°C for 5 min; and
wash III, rinse 20 times at 37°C). The slides were dried
by centrifugation and scanned using an Axon 4000B
scanner (Molecular Devices, Sunnyvale, CA, USA). The
signal intensities of Cy5 fluorescence in each spot were
analyzed using GenePix 4.1 software (Molecular Devices)
and processed using the R program. We filtered out spots
for which the flag was <0, and spots that passed this cri-
teria were normalized using the 75% media scaling
normalization method. Normalized spot intensities were
converted into gene expression log2 ratios for the control
and treatment groups. Spots with log2 ratios ≤ –1 or ≥1
and P values <0.05 were selected for further analysis. The
differentially expressed miRNAs were subjected to hier-
archical cluster analysis using average linkage and Pearson
correlation as a measure of similarity.
Quantification of miRNA expression
miRNA expression was quantified by qRT-PCR to confirm
the upregulation of expression of the miRNA targets that
were detected using miRNA array analysis from the
transplanted nerve grafts and whole blood of the animals
in the experimental groups at 7 d after surgery. The ex-
pression of each miRNA in nerve graft and whole blood
was represented relative to the expression of U6 small nu-
clear RNA (U6 snRNA), which was used as an in-
ternal control. For the serum, 25 fmol of single-stranded
cel-miR-39, synthesized by Invitrogen (Invitrogen,
Carlsbad, CA, USA), was spiked into 400 μL of serum as
an internal control for the expression of each miRNA. In
the reverse transcription step, each RNA sample was
reversely transcribed to cDNA by using TaqMan®
MicroRNA Reverse Transcription Kit (Applied Biosystems,
Foster City, CA, USA) according to the manufacture’s in-
struction. In the PCR step, PCR products were mixed with
the TaqMan Universal PCR Master Mix (No UNG, PN
4324018, Applied Biosystems) and specific miRNA primers
from the TaqMan MicroRNA Assays (Applied Biosystems).
The following TaqMan MicroRNA Assays were used in this
study: mmu-miR-125b-3p (assay ID: 002378), mmu-miR
-467b* (001684), mmu-miR-672 (002327) for nerve grafts
and mmu-miR-320 (002277), mmu-miR-423-5p (002340),
mmu-miR-762 (002028) for whole blood and serum and
U6snRNA (001973), cel-miR-39 (000200) for internal con-
trol. The qRT-PCR reactions were performed by a 7500
Real time PCR system (Applied Biosystems) and each sam-
ple reactions were run in triplicate. We evaluated miRNA
expression by calculating the relative expression values in 6
samples and comparing them with those from the control
samples; the induction was expressed as fold change in
miRNA expression relative to that for the control.
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variance (ANOVA) and an appropriate post hoc test to
compensate for multiple comparisons (SigmaStat, Jandel,
CA, USA). P values of <0.05 were considered significant.
Results
Dysregulated miRNA targets in miRNA array analysis
The miRNA array experiments showed an approximately
2-fold difference in the expression of miRNAs in the
whole blood and nerve graft samples at 7 d after initial
surgery for these 3 groups, that is, those with an isograft
and those with an allograft with or without FK506 treat-
ment (P < 0.05; n = 2 for each subgroup). The hierarch-
ical cluster analysis of all miRNAs expressed in the
whole blood and nerve graft is shown in Figure 1. Un-
supervised hierarchical clustering was used to separate
the samples from different experimental subjects into
different groups. The miRNA targets that were signifi-
cantly dysregulated in the array experiments are shown
in Table 1. In the whole blood samples, when compared
to those with untreated isograft, there were 5 (miR-720,
miR-709, miR-2145, miR-1195, and miR-690) and 4 (let-
7d, miR-26a, let-7i, and left-7a) downregulated miRNA
targets in the mice receiving allograft without and with
FK506 treatment, respectively. In addition, there was sig-
nificant expression of 3 miRNAs (miR-320, miR-762,Figure 1 Unsupervised hierarchical clustering of the expression of mi
the whole blood and nerve grafts of Balb/c mice at postoperative day 7 w
(C57BL/6→ Balb/c), and (3) allografts (C57BL/6→ Balb/c) with daily injectioand miR-423-5p) in the mice receiving an allograft with
FK506, when compared to those mice receiving allograft
without FK506. When compared to mice with untreated
isografts, the mice receiving allografts with or without
FK506 immunosuppression did not show increased
miRNA target levels. In the nerve graft, 1 miRNA (miR-
125b-3p) was upregulated in the mice receiving allo-
grafts without FK506, compared to those with untreated
isografts. In addition, there was significant expression of
3 miRNAs (miR-125b-3p, miR-672, and miR-467b*) in the
mice receiving an allograft with FK506, when compared to
those mice receiving an allograft without FK506. No in-
creased miRNA target expression and decreased expres-
sion of only 1 miRNA target (miR-2140) were found in
the mice that received an allograft with FK506 treatment
and those with untreated isografts, respectively. The
miRNA array data have been deposited in Gene Expres-
sion Omnibus (accession numbers: GSE48969).
Profiling of miRNA expression
Because miRNAs are directly transcribed to cope with
physiological or pathological alterations, the upregulated
miRNAs were further analyzed by qRT-PCR, which was
expected to give more meaningful results. Three
miRNAs (miR-320, miR-762, and miR-423-5p) in the
circulation and 3 miRNAs (miR-125b-3p, miR-672, andRNAs. Hierarchical clustering of miRNA differentially expressed in
ith untreated isografts (Balb/c→ Balb/c), (2) untreated allografts
n of 1 mg/kg FK506 for immunosuppression.
Table 1 miRNA targets that were significantly dysregulated in the whole blood and the grafted nerves by the miRNA
array experiments in the untreated isograft, untreated allograft, and allograft with FK506 immunosuppression groups
Whole Blood
Allograft v.s. Sham operation Allograft with FK506 v.s. Sham operation Allograft with FK506 v.s. Allograft
increased miRNA targets log2 (ratio) increased miRNA targets log2 (ratio) increased miRNA targets log2 (ratio)
No No miR-320 1.44
miR-762 1.37
miR-423-5p 1.08
decreased miRNA targets log2 (ratio) decreased miRNA targets log2 (ratio) decreased miRNA targets log2 (ratio)
miR-720 -1.75 let-7d -1.43 No
miR-709 -1.13 miR-26a -1.42
miR-2145 -1.03 let-7i -1.44
miR-1195 -1.01 let-7a -1.25
miR-690 -1.01
Nerve grafts
Allograft v.s. Sham operation Allograft with FK506 v.s. Sham operation Allograft with FK506 v.s. Allograft
increased miRNA targets log2 (ratio) increased miRNA targets log2 (ratio) increased miRNA targets log2 (ratio)
miR-125b-3p 1.02 No miR-125b-3p 1.54
miR-672 1.15
miR-467b* 1.03
decreased miRNA targets log2 (ratio) decreased miRNA targets log2 (ratio) decreased miRNA targets log2 (ratio)
No miR-2140 -1.16 No
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quantification and validation. Expression of the miRNAs
was considered differentially regulated if the mean values
for all samples (n = 6 in each group at each time point)
demonstrated more than 2-fold difference compared
with those for the control samples (P value <0.05) by
qRT-PCR. With around 4- to 6-fold expression, miR-320,
miR-762, and miR-423-5p were significantly upregu-
lated in the whole blood of the mice receiving allograft
with FK506 at 1, 3, 7, 10, and 14 d after nerve
allotransplantation, when compared to those mice receiv-
ing allograft without FK506 (Figure 2A). The expression of
these 3 miRNA targets (miR-320, miR-762, and miR-423-
5p) was found to be significantly upregulated in the serum
(Figure 2B). In the nerve graft, only miR-125-3b and miR-
672 were significantly upregulated in the mice receiving
allograft with FK506 only at 7 d, but not at 1, 3, 10, or 14
d, after nerve allotransplantation (Figure 2C). However,
the increase of miR-125-3b and miR-672 at 7 d was only a
little, albeit significantly. No significant expression of miR-
467b* was noted in the nerve graft within 2 weeks after
nerve allotransplantation. In addition, no significant ex-
pression of these 3 circulating miRNAs (miR-320, miR-
762, and miR-423-5p) was found in the nerve graft of the
mice receiving allograft with FK506 (Figure 3).Expression of circulating miRNAs after discontinuation of
FK506
To clarify whether the expression of circulating miRNAs
was induced by FK506 per se, that is, regardless of the
nerve allotransplantation, we quantified the expression
of miR-320, miR-762, and miR-423-5p in the serum
drawn from sham-operated mice with or without daily
FK506 injection for 7 d by using qRT-PCR. The results
revealed no significant difference between these 2 groups
(Figure 4A). In addition, in the Balb/c mice with allo-
graft and FK506 immunosuppression, the expression of
all the 3 upregulated circulating miRNAs showed a sig-
nificant decrease at 2, 4, and 6 d after discontinuation of
FK506 injection; the expression was even markedly
lower than that in the mice at 7 d after untreated nerve
allotransplantation.
Discussion
In this study, we established the profile of circulating
miRNA expression using a murine model of nerve
allotransplantation. miR-320, miR-762, and miR-423-5p
were significantly upregulated in the whole blood and
serum, but not in the nerve graft, of the mice receiving
an allograft with FK506 immunosuppression at 1, 3, 7,
10, and 14 d after nerve allotransplantation. All these 3
Figure 2 Quantification of upregulated miRNA targets detected by miRNA arrays, by qRT-PCR within 2 weeks after nerve
allotransplantation in (A) whole blood, (B) sera, and (C) nerve grafts. Bars represent mean ± SEM values of 6 experiments; *P < 0.05.
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crease at 2, 4, and 6 d after discontinuation of FK506
injection.
The introduction of powerful immunosuppressive
therapies in the past 4 decades has reduced the inci-
dence of acute rejection in transplant recipients. How-
ever, the lack of noninvasive biomarkers of rejection
precludes optimization of therapeutic intervention. Allo-
graft biopsy is the gold standard for diagnosis ofconditions like acute rejection, disease recurrence, and
drug toxicity [38,39]. However, whereas minimal risk is
involved in obtaining an allograft biopsy of solid organs,
it is not practical to acquire a nerve biopsy in the clinical
setting. Moreover, the histological evaluation of biopsies
remains subjective and is associated with some degree of
variability depending on the pathologist evaluating the
tissue sample [39-41]. Circulating miRNAs, owing to the
noninvasive nature of their detection, their disease
Figure 3 Quantification of the circulating miRNA targets in the nerve graft within 2 weeks after nerve allotransplantation by qRT-PCR.
Bars represent mean ± SEM values of 6 experiments; *P < 0.05.
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their detection and monitoring, may be developed as ex-
cellent biomarkers of allograft injury and function [42].
Sui et al. reported the first comparison using microarray
analysis of miRNA expression and qRT-PCR confirm-
ation in acute rejection after renal transplantation and
identified 8 upregulated and 12 downregulated miRNAs
differentially expressed in acute rejection after renal
transplantation [43]. Anglicheau et al. showed a set of
miRNAs to be highly deregulated in renal biopsy
samples and peripheral blood mononuclear cells of pa-
tients with acute rejection [44]. Intragraft levels of miR-
142-5p, miR-155, miR-223, miR-10b, miR-30a-3p, and
let-7c have been proposed to have diagnostic value for
acute rejection, with miR-142-5p, miR-155, and miR-223
each predicting acute rejection with >90% sensitivity and
specificity. Upregulated miR-142-5p, miR-155, and miR-
223 were strongly linked to intragraft levels of CD3 and
CD20 mRNA, suggesting that the altered expression of
miRNAs might be due to graft-infiltrating immune cells
[44]. Asaoka et al. proposed that the different miRNA
expression patterns can be used to identify novel bio-
markers and therapeutic targets for immunosuppressiveFigure 4 Quantification of the circulating miRNA targets by qRT-PCR in
allotransplantation with or without daily FK506 injection and (B) at 2, 4
receiving nerve allotransplantation with FK506 immunosuppression foragents; their study involved evaluation of the expression
of 384 mature miRNAs in intestinal mucosal biopsy
specimens from recipients with small bowel transplant-
ation [45]. Recently, Lorenzen et al. found the urinary
miR-210 to be the only specific urinary biomarker of
acute cellular rejection in transplant patients [46]. Fur-
thermore, differential expression of miR-142-3p, miR-
204, and miR-211 was also observed in urine samples
between patient groups with chronic allograft dysfunc-
tion [47]. Gehrau et al. also reported that the abnormal
levels of circulating cell-free miRNAs correlate with spe-
cific hepatic injury and thus may serve as feasible moni-
toring and outcome predictive biomarkers in liver
transplantation [48]. Despite the few studies published
in the field regarding the relationship between circulat-
ing miRNAs and status of allograft, the potential of
miRNAs as biomarkers for diagnosis of acute or chronic
rejection and the response to therapy in noninvasive
monitoring might be expected to have critical impact in
the transplant field in the immediate future.
Among the 3 upregulated circulating miRNAs, miR-
320 was reported to increase more than 2.5-fold in
neurodegeneration [49]. After injury, miR-320 might(A) the serum drawn from sham-operated mice at day 7 after nerve
, and 6 d after discontinuation of FK506 injection in the mice
7 d. Bars represent mean ± SEM values of 6 experiments; *P < 0.05.
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onal development [50]. In Neuro-2A cells, the increase
in the levels of miR-320 for 3 d markedly increased
neurite length, with possible involvement of the identi-
fied miR-320 targets cAMP-regulated phosphoprotein
19 kDa (ARPP-19) and semaphorin 3A detected by in
silico analysis [50]. In addition, the neural precursor
cell-enriched miR-762 could translationally
downregulate adenosyl methionine decarboxylase 1
(Amd1), a key enzyme in the polyamine synthesis path-
way, to regulate both embryonic stem cell self-renewal
and differentiation into neural lineage [51]. miR-762 has
also been reported to negatively regulate the innate
defense genes RNase7, ST2, and Rab5a [52]. Elevated
serum levels of miR-423-5p correlated with important
clinical prognostic parameters in systolic heart failure
patients [53] and served as a diagnostic biomarker for
heart failure caused by dilated cardiomyopathy [54] or
left ventricle remodeling after myocardial infarction [55].
miR-423 has been defined also as a new oncogenic
miRNA in hepatocellular carcinoma through the sup-
pression of the tumor suppressor p21Cip1/Waf1 [56].
No association of miR-423-5p with neurological illness
or immunological condition has been reported in the
literature.
The underlying mechanistic basis for circulating
miRNA expression during an episode of acute rejection
remains an area of utmost interest, which is just in its
early stages of research. In this study, our main goal is to
find the possible upregulated circulating miRNAs after
nerve allotransplantation in the mice without immuno-
suppression, and then determine whether these identi-
fied circulating miRNAs may be used as targets for
monitoring or therapeutic intervention. However, when
compared to those with untreated isograft, no increased
miRNA target was found in the circulation of the mice
receiving allograft with or without FK506 treatment. We
only found 3 significantly expressed circulating miRNAs
(miR-320, miR-762, and miR-423-5p) in the mice receiv-
ing allograft with FK506 against those without FK506
immunosuppression. However, in this study, daily FK506
injection for 7 d in sham-operated mice revealed no sig-
nificant increase of these 3 circulating miRNAs in the
serum, which implies that the expression of circulating
miR-320, miR-762, and miR-423-5p can only be induced
under FK506 immunosuppression, but not under allo-
geneic condition, and therefore may potentially serve as
biomarkers for sufficient immunosuppression. In addi-
tion, the immunosuppressive drug FK506 has been
proved to have neuroprotective and neurotrophic actions
in experimental models, that is, it increases neurite
elongation and accelerates the rate of nerve regeneration
in vitro and in vivo [57,58]. Furthermore, recent studies
have suggested that the differentiation of differentsubsets of CD4 T cells is regulated by the signals present
in the tissue microenvironment (Lal et al., 2011; Gao
et al., 2012) and that miRNAs play an important role in
the development and function of all subsets of CD4 T
cells (Sethi et al., 2013). miRNAs are differentially
expressed between the mice receiving allogeneic grafts
with and without immunosuppression, suggesting their
potentially important regulatory functions in graft rejec-
tion. Whether these circulating miRNAs play a role in
the nerve regeneration-enhancing activity of FK506 re-
quires further investigation.
There are certain limitations to our study. First, molecu-
lar insights into the origins as well as mechanisms under-
lying the dysregulation of circulating miRNAs could not
be provided. In this study, we have demonstrated that
none of the 3 circulating miRNAs (miR-320, miR-762, and
miR-423-5p) was significantly expressed in nerve allo-
grafts; effective models for identifying the origin of these
expressed circulating miRNAs are still not available. Sec-
ond, although FK506 administered subcutaneously at
1 mg/(kg · d) is a standard and effective protocol for im-
munosuppression after nerve allotransplantation in ro-
dents and in humans [17,20,24] and we have also
demonstrated that discontinuation of FK506 injection will
markedly downregulate these circulating miRNAs at 2, 4,
and 6 d and thereafter following discontinuation, the re-
sponse of these expressed circulating miRNAs to the con-
ditions of under- or over-immunosuppression or even to
organ toxicity remains obscure. Third, in the rejection of
nerve allografts typically occurring within 7 d of trans-
plantation in the absence of host immunosuppression
[23], although an abrupt discontinuation of FK506 injec-
tion is expected to induce an ongoing acute rejection of
the nerve allograft, there is still a time discrepancy be-
tween the discontinuation of immunosuppression and the
beginning of rejection. The relationship between the de-
creased expression of these circulating miRNAs after the
discontinuation of immunosuppression and the beginning
of rejection is yet to be defined. Finally, the impact on the
circulating miRNAs expression by nerve regeneration
acrossing the nerve allograft should be considered and
clarified in further experiment.Conclusions
In conclusion, this study provides the first insights into
the expression of circulating miRNAs in nerve allotrans-
plantation with or without FK506 immunosuppression.
We identified the circulating miR-320, miR-762, and miR-
423-5p as potential biomarkers for monitoring the im-
munosuppression status of nerve allografts. However,
further research is required to evaluate the prognostic
value of these markers and to expand the miRNA signa-
ture for disease progression.
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